American Urological Association Clinical Guidelines on Overactive Bladder (OAB) for Urologists: A Panel Webcast
| Title: | American Urological Association Clinical Guidelines on Overactive Bladder (OAB) for Urologists: A Panel Webcast |
| Topic: | Urology |
| Relevant Terms: | Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB), Pelvic Floor Muscle |
| Primary Audience: | Urologists, urology care team providers such as physician's assistants and nurse practitioners |
| Launch Date: | 30-Nov-12 |
| Credits: | 0.75 AMA PRA Category 1 Credit™ |
| Expiration Date: | 29-Nov-13 |
| Curriculum Name: | Clinical Guidelines on Overactive Bladder (OAB) for Urologists |
Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Apply the most recent AUA clinical guideline recommendations and best practices to assess and diagnose urological symptoms
- Identify and maximize screening opportunities
- Skillfully treat and manage urological conditions
Faculty
E. Ann Gormley, MD
Professor of Surgery
Urology
Dartmouth-Hitchcock Med. Ctr.
Lebanon, NH
Deborah J. Lightner, MD
Professor of Urology
Department of Urology
Mayo Clinic
Rochester, MN
Toby C. Chai, MD, FACS
Professor of Surgery
Urology Division
University of Maryland Medical Center
Baltimore, MD
Professor of Surgery
Urology
Dartmouth-Hitchcock Med. Ctr.
Lebanon, NH
Deborah J. Lightner, MD
Professor of Urology
Department of Urology
Mayo Clinic
Rochester, MN
Toby C. Chai, MD, FACS 
Professor of Surgery
Urology Division
University of Maryland Medical Center
Baltimore, MD
AUA Clinical Guideline on Overactive Educational Video on OAB for Urologists
Commercial Support Acknowledgement
This activity was supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.
CME Information
Method of physician participation in the learning process:
CME Information
Method of physician participation in the learning process:
- Read through the CME information.
- Click "Enter the Activity" link at the bottom of the page.
- Login. If you do not have an account, you will be prompted to create one. It is recommended that you use your email address for your user name and a password when creating your account.
- To claim credit, complete the pre-test, view the webcast, pass the posttest with 80% accuracy and submit the evaluation.
- Print your certificate for documentation.
Medium or combination of media used
Online
Online
Hardware/Software Requirements
PC-compatible computer running Windows XP, or a Macintosh computer running OS X 10.1 or later, or a Linux computer capable of running Mozilla Firefox 3.0 or later. Processor speed of 800 MHz (1GHz preferred). A minimum of 128 MB of RAM (more preferred). A modem speed of at least 56k (broadband preferred). Internet browser should be one of the following: Internet Explorer 8.0 or later, Firefox 3.0 or later, Chrome 4.0 or later, or Safari 4.0 or later. Software requirement: Adobe Acrobat Reader 9 or newer.
Estimated time to complete the educational activity
0.75 hours
Statement of Need
Overactive bladder (OAB), defined as 'urgency, with or without urinary incontinence, usually with frequency and nocturia,' affects 33 million men and women in the United States. Overall, up to 17% of American adults suffer from overactive bladder; yet, only 16% of patients with OAB will receive treatment.
Urologists - Screening and Assessment
Health care providers demonstrate a clear practice gap in identifying, assessing and treating OAB. For example, one study found that that even when a patient presented with new or worsening incontinence, only 19% of physicians obtained an incontinence history and only 22% conducted a physical examination. Encouragingly, outcomes data from previous continuing professional education on urological topics suggests that health care professionals are eager to learn about updated practice guideline recommendations, implement strategies for best care, and improve their practice in the assessment, diagnosis, and management of urological conditions.
As the prevalence of OAB continues to increase and options for diagnosis and evidence based treatment continue to change evolve, urologists' need and interest persists for continued education on this topic continues to grow. There is continually emergent literature on OAB and urologists can utilize effective educational opportunities to continually enhance their knowledge and practice relating to OAB, and most importantly better patient outcomes.
New AUA Clinical Practice Guideline on Overactive Bladder (OAB)
To ensure consistent, high quality, evidence-based treatment of patients with OAB, the AUA released a Clinical Practice Guideline on Overactive Bladder (OAB) in May 2012. The Guideline focuses on the diagnosis and treatment of OAB and contains useful tools for providers such as a treatment algorithm. The American Board of Urology in conjunction with the AUA continues to emphasize the importance of AUA Guidelines which serve as the basis for clinical diagnostic and treatment formulation.
Program Purpose and Description
The purpose of this activity is to provide urologists with AUA's new clinical practice guideline on overactive bladder to augment their knowledge of screening methods and identification and treatment options for OAB in the convenience of their office or practice. Special emphasis will be placed on enhanced communication with patients in regards to treatment. Content will be delivered through an educational video based largely on the new AUA guideline on OAB. This activity consists of viewing the OAB video panel discussion and answering a series of questions based on the content of the video.
The purpose of this activity is to provide urologists with AUA's new clinical practice guideline on overactive bladder to augment their knowledge of screening methods and identification and treatment options for OAB in the convenience of their office or practice. Special emphasis will be placed on enhanced communication with patients in regards to treatment. Content will be delivered through an educational video based largely on the new AUA guideline on OAB. This activity consists of viewing the OAB video panel discussion and answering a series of questions based on the content of the video.
Accreditation
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstration
Planners and Principal Faculty Credentials and Disclosures
E. Ann Gormley, MD
Dartmouth-Hitchcock Med. Ctr.
1 Medical Center Drive
Lebanon, NH
Disclosures: National Institute of Health – NIDDK
E. Ann Gormley, MD
Dartmouth-Hitchcock Med. Ctr.
1 Medical Center Drive
Lebanon, NH
Disclosures: National Institute of Health – NIDDK
Kathryn L. Burgio, PhD
University of Alabama at Birmingham
Department of Medicine
Birmingham, AL
Disclosures: Pfizer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Toby C. Chai, MD, FACS
Professor of Surgery
Urology Division
University of Maryland Medical Center
Baltimore, MD
Disclosures: Allergan: Consultant or Advisor, Scientific Study or Trial; National Institutes of Health: Scientific Study or Trial; Taris Biomedical: Other; Ion Channel, Inc.: Consultant or Advisor; New England Research Institute: Scientific Study or Trial
Darryl S. Chutka, MD
Associate Professor of Medicine
Mayo Clinic
Rochester, MN
Disclosures: Nothing to disclose
Professor of Surgery
Urology Division
University of Maryland Medical Center
Baltimore, MD
Disclosures: Allergan: Consultant or Advisor, Scientific Study or Trial; National Institutes of Health: Scientific Study or Trial; Taris Biomedical: Other; Ion Channel, Inc.: Consultant or Advisor; New England Research Institute: Scientific Study or Trial
Darryl S. Chutka, MD
Associate Professor of Medicine
Mayo Clinic
Rochester, MN
Disclosures: Nothing to disclose
Deborah J. Lightner, MD
Mayo Clinic
Department of Urology
Rochester, MN
Disclosures: Nothing to disclose
Mayo Clinic
Department of Urology
Rochester, MN
Disclosures: Nothing to disclose
Elspeth McDougall, MD, FRCSC, MHPE
Associate Dean of Continuing Z& Simulation Medical Education
Director, Minimally Invasive Surgery Education Center
Chair, AUA Office of Education
University of California – Irvine
Irvine, CA
Disclosures: Ethicon Endo-Surgery: Other; Karl Storz Endoscopy American: Other
Harriette Miles Scarpero, MD
St. Thomas Hospital
Medical Plaza East
Nashville, TN
Disclosures: Pfizer, Inc.: Scientific Study or Trial; American Medical Systems (AMS): Consultant or Advisor; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Warner Chilcott: Meeting Participant or Lecturer
Abid Khan, MHS
Associate Dean of Continuing Z& Simulation Medical Education
Director, Minimally Invasive Surgery Education Center
Chair, AUA Office of Education
University of California – Irvine
Irvine, CA
Disclosures: Ethicon Endo-Surgery: Other; Karl Storz Endoscopy American: Other
Harriette Miles Scarpero, MD
St. Thomas Hospital
Medical Plaza East
Nashville, TN
Disclosures: Pfizer, Inc.: Scientific Study or Trial; American Medical Systems (AMS): Consultant or Advisor; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Warner Chilcott: Meeting Participant or Lecturer
Abid Khan, MHS
American UrologicalAssociation
Health Policy:Guidelines
Linthicum, MD
Disclosures:Nothing to disclose
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Copyright
© 2012 American Urological Association Education and Research, Inc.®
Privacy Policy
http://www.auanet.org/content/education-and-meetings/statements-and-policies.cfm?sub=confidentiality
Contact
cme@AUAnet.org
